Results 151 to 160 of about 3,663,740 (300)

Survival rate and need for maintenance of cover-denture prostheses borne on three or less abutment teeth: ten-year results. [PDF]

Head Face Med
Schuster L, Ketabi AR, Dammaschke T, Lauer HC.   +3 more
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Correction: The Survival Rate of Hospitalized Lupus Patients With Overlap Disease. [PDF]

Cureus
Jaf JA, Faezi ST, Kasaeian A.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

One-year survival rate and factors associated with stage IV colorectal cancer at National General Hospital in Indonesia. [PDF]

Front Med (Lausanne)
Wildan A, Christabel EV, Rinaldi I, Abdullah M, Makmun D.   +4 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Re: "impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study". [PDF]

Ann Intensive Care
Li M, Xu M.
europepmc   +1 more source

Effect of OKT3 on survival and rate of retransplantation [PDF]

, 1987
Esquivel, CO, Fung, JJ, Gordon, RD, Iwatsuki, S, Makowka, L, Markus, BH, Starzl, TE   +6 more
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Response to the letter regarding "Survival rate of dental implant in the anterior mandible: a retrospective study". [PDF]

J Korean Assoc Oral Maxillofac Surg
Kim SY, Kim YL, Kong HJ.
europepmc   +1 more source